Primary objectives:
* Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including dexamethasone (experimental arm) instead of prednisone (standard arm) * Randomization R2, only patients with high risk LBL eligible: to examine, whether the probability of event-free survival (pEFS) in these patients can be improved by receiving an intensified treatment arm versus a standard treatment arm (as used in the EURO-LB 02)
newly diagnosed lymphoblastic lymphoma
age <18 years
patient enrolled in a participating center
written informed consent of patient (>14 years of age or according to local law and regulation) and parents to trial participation and transfer and processing of data
lymphoblastic lymphoma as secondary malignancy
non-lymphoma related relevant medical, psychiatric or social conditions incompatible with trial treatment, including among others
prior organ transplant
severe immunodeficiency
8
Treatment groupsSee each treatment group below.
University Hospital Muenster
Lead sponsor
Deutsche Krebshilfe e.V., Bonn (Germany)
Collaborator